Current Opinion in Hematology volume 19, issue 1, P3-13 2012 DOI: 10.1097/moh.0b013e32834da9a4 View full text
|
|
Share
Antonio M. Risitano

Abstract: Immunosuppression by h-ATG and CyA remains the standard of care for aplastic anemia patients lacking a low-risk transplant procedure, resulting in a 60-70% response rate. Rabbit-ATG, cyclophosphamide and alemtuzumab demonstrated a biological activity, but resulted in inferior outcome as compared with h-ATG; thus, they are not recommended as front-line therapy of aplastic anemia.